SANOFI

Sanofi’s Q2 2026 aide‑mémoire pre‑emptively explains non‑comparable items, currency swings and share‑count changes, giving analysts a deeper view of hidden risks and AI‑driven growth potential.

EU probes Sanofi’s Efluelda marketing, weighing anti‑competitive claims and potential €50‑80 million revenue hit for the 32 % market‑share holder.

Sanofi secures EU approval for Cenrifki, Japan clearance for Sarclisa, and appoints Dr. Paulo Fontoura to lead R&D, expanding its neuro‑ and oncology portfolio.

Sanofi’s Japan approval of SC Sarclisa and its first‑in‑class CirCLIQ injector could boost multiple myeloma care with home‑based, cost‑effective treatment, opening new revenue streams and value‑based pricing.

Sanofi’s EU approval of Sarclisa SC offers multiple‑myeloma patients a safe, non‑inferior alternative to IV treatment with fewer infusion reactions, greater convenience, and improved quality‑of‑life.

Sanofi shifts capital to R&D, easing short‑term earnings but boosting long‑term oncology and rare‑disease pipeline growth.